

**Reply**

We have found no data in the literature to support Dr. Hamburger's assumption that in metastases radiiodine uptake will continue to increase with prolonged exposure to high TSH levels. Although this is a theoretical possibility, there are practical reasons for minimizing the duration of hypothyroidism. Protracted hypothyroidism is poorly tolerated by patients, it may have medical complications and it may be associated with tumor growth. Accordingly, we have chosen to administer radiiodine at the time of maximal pituitary TSH secretion and to keep the period of hypothyroidism as short as possible.

After thyroidectomy residual uptake of radiiodine in the thyroid bed is usually associated with residual normal, functioning thyroid tissue. Such uptake can often be ablated with a single dose of I-131. Successful ablation of thyroid bed uptake should not be confused, however, with eradication of uptake in functioning metastases; the latter often requires repeated treatment with I-131.

Low iodine diets may augment tumor uptake of I-131 by decreasing the amount of stable, carrier iodine in the body; such diets require rigid patient compliance in view of the widespread introduction of iodine into food and food additives. The use of ethacrynic acid to deplete body iodine as advocated by Hamburger (1), however, may cause serious side effects. Nemec et al. reported clinical intolerance to ethacrylic acid pretreatment such as drowsiness, muscular weakness, arterial hypotension, and manifestations of previously latent tetany (2). When ethacrylic acid is stopped renal iodide clearance falls sharply, which results in increased body retention of I-131 and increased whole body radiation; this effect is independent of I-131 uptake in the tumor. As Sisson has observed, a similar effect of increased tumor and whole body radiation can be achieved simply by increasing the dose of I-131 (3).

**REFERENCES**


**Glucoheptonate Kidney Studies**

The comparison of Tc-99m glucoheptonate renal imaging with the i.v. urogram for the detection of mass lesions, reported by Leonard et al. (1), was impressive (accuracy 85% against 71%). Since their findings confirm my impression and that of many other clinical groups using Tc-99m glucoheptonate since 1974, it is surprising that no previous report on glucoheptonate imaging has appeared in the medical literature. (Glucoheptonate has been reported to be equivalent to iod hippurate for the evaluation of renal function (2).) This report (1) with its excellent results is, therefore, particularly welcome, since one is reluctant to recommend a new procedure over a well-established test solely on the basis of anecdotal experience. The report was incomplete, however, and the results as reported were almost certainly less favorable to glucoheptonate than actual clinical experience would indicate, considering that six of 47 cases were excluded because urograms were considered inadequate for interpretation.

It would be of interest to know what occurred in the clinical setting, in addition to the reported results of comparative evaluation later “reviewed independently by two observers without benefit of clinical history.” How were the 47 radiographic and radionuclide studies initially reported, and how did this affect clinical management? Were six to eight urograms initially considered inadequate and a radionuclide study therefore recommended? If the initial diagnostic study, whether radiographic or radioactive, were considered adequate, why was the other study done? Unless this was a prospective clinical research project, the second study should have been considered redundant, before knowing the results of this comparison report. What were the clinical indications for these studies and in the other patients who had glucoheptonate renal imaging alone? I doubt that a scan would have been preferred initially over i.v. urography (IVU) for suspicion of neoplasm. Hereafter, the most common indication for radionuclide studies has been inability to perform IVU because of either allergy to iodine or impaired kidney function; less commonly to determine the cause of impaired function, or of hypertension, of the vascularity of a lesion demonstrated by IVU; or to evaluate other aspects of function, such as obstructive uropathy.

The authors (1) state that the radionuclide flow study was not found “to be reliably helpful in evaluating the vascularity of mass lesions.” They must mean that a cyst may mimic a mass lesion, as has been reported previously. How accurate was the flow study in differentiating cysts from mass lesions? I have found the flow study extremely important in this regard; including one patient with hypertension shown to have a highly vascular kidney lesion, said to be a cyst by ultrasound but proved to be hypernephroma. (Ultrasound was redundant as well as wrong in that case, since biopsy is indicated unless a lesion appears avascular as well as cystic by ultrasound.)

The authors (1) suggest the possibility of missing extrarenal disease if only radionuclide studies are performed, but add that no significant extrarenal disease was detected by IVU in their cases. In how many of their patients was significant extrarenal disease detected in radionuclide studies? In one published report, clinically unsuspected significant findings were discovered in 22% of patients by radionuclide studies (3). I continue to be amazed at the high incidence of significant incidental findings in Tc-99m kidney studies, visualized primarily in a vascular flow study. Two of the most striking examples have been published (4,5). I have also found aortic aneurysm and pseudo-aneurysm; extrarenal neoplasm, inflammatory disease, and hematoma; and occlusive peripheral arterial disease. Conversely, when the vascular flow study has been done to evaluate arterial disease, kidney abnormalities are often discovered.

I am sure that Dr. Leonard's article will encourage more extensive use of this important diagnostic modality, and I hope other groups will evaluate their experience with Tc-99m glucoheptonate kidney studies for publication.

**LETTERS TO THE EDITOR**

**Ralph S. Wolfstein**

Century City Hospital

Los Angeles, California

---

**Dorothea Hellman**

James Woolfenden

Schuyler Hills

Pima Professional Plaza

Tucson, Arizona